Élena Elez
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer Genomics and Diagnostics, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer(2020)2,821 cited
- → Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer(2017)1,471 cited
- → Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer(2019)1,423 cited
- → Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164(2019)988 cited
- → Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study(2017)532 cited
- → Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study(2021)518 cited
- → Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study(2017)511 cited
- → Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial(2020)498 cited
- → Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis(2017)399 cited
- → Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial(2021)396 cited